Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
作者： H Tilly , S Castaigne , D Bordessoule , P Casassus , P Y Le Prisé
关键词: Internal medicine 、 Leukemia 、 Intensive chemotherapy 、 Randomized controlled trial 、 Gastroenterology 、 Multicenter trial 、 Clinical trial 、 Medicine 、 Cytarabine 、 Low dose cytarabine 、 Surgery 、 Myeloid
摘要: We conducted a randomized multicenter trial comparing low-dose cytarabine (LD ARA-C) (20 mg/m2 for 21 days) with an intensive chemotherapy (rubidazone [a daunorubicin-derived agent], 100 4 days, ARA-C 200 7 in 87 patients over 65 years of age de novo acute nonlymphocytic leukemia (ANLL). Forty-one received LD and 46 chemotherapy. The number complete remissions (CRs) but also early deaths was higher the group, while partial (PRs) failures were more frequent group (P less than .001). Infectious complications during induction treatment numerous severe .01). Patients treated required fewer RBC transfusions .02), platelet .01), had shorter hospital stay Overall survival CR duration not significantly different either group. In PR those CRs identical. conclude that selected elderly ANLL may be obtained chemotherapy, ARA-C, is lower, long-lasting PRs are obtained, resulting similar overall survival.
sci-hub.se 参考文章(28)
C. Haanen, R. De Bock, U. Jehn, Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia. Annals of Hematology. ,vol. 48, pp. 255- 261 ,(1984) , 10.1007/BF00320395
S Castaigne, MT Daniel, H Tilly, P Herait, L Degos, Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood. ,vol. 62, pp. 85- 86 ,(1983) , 10.1182/BLOOD.V62.1.85.85
KA Foon, J Zighelboim, C Yale, RP Gale, Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood. ,vol. 58, pp. 467- 470 ,(1981) , 10.1182/BLOOD.V58.3.467.BLOODJOURNAL583467
S B Kahn, C B Begg, J J Mazza, J M Bennett, H Bonner, J H Glick, Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology. ,vol. 2, pp. 865- 870 ,(1984) , 10.1200/JCO.1984.2.8.865
H D Preisler, A Raza, M Barcos, N Azarnia, R Larson, I Walker, M Browman, H Grunwald, P D'Arrigo, T Doeblin, High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. Journal of Clinical Oncology. ,vol. 5, pp. 75- 82 ,(1987) , 10.1200/JCO.1987.5.1.75
B D Cheson, D M Jasperse, R Simon, M A Friedman, A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. Journal of Clinical Oncology. ,vol. 4, pp. 1857- 1864 ,(1986) , 10.1200/JCO.1986.4.12.1857
B Löwenberg, R Zittoun, H Kerkhofs, U Jehn, J Abels, L Debusscher, C Cauchie, M Peetermans, G Solbu, S Suciu, On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology. ,vol. 7, pp. 1268- 1274 ,(1989) , 10.1200/JCO.1989.7.9.1268
Yves Beguin, Jean Bury, Georges Fillet, Georges Lennes, Treatment of acute nonlymphocytic leukemia in young and elderly patients. Cancer. ,vol. 56, pp. 2587- 2592 ,(1985) , 10.1002/1097-0142(19851201)56:11<2587::AID-CNCR2820561109>3.0.CO;2-8
J REES, Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. The Lancet. ,vol. 328, pp. 1236- 1241 ,(1986) , 10.1016/S0140-6736(86)92674-7
Hiroto Ishikura, Hiroyoshi Sawada, Toshiro Okazaki, Toshihiro Mochizuki, Yoichiro Izumi, Morihisa Yamagishi, Haruto Uchino, The effect of low dose Ara-C in acute non-lymphoblastic leukaemias and atypical leukaemia British Journal of Haematology. ,vol. 58, pp. 9- 18 ,(1984) , 10.1111/J.1365-2141.1984.TB06054.X